Group 1 - The stabilization period for the global offering of Huazhang Biotechnology-B (02396) ended on January 16, 2026, which is 30 days after the deadline for submitting the Hong Kong public offering application [1][4] - There was no over-allocation of shares under the international offering, and therefore, the over-allotment option was not exercised and has expired as of January 16, 2026 [1][4] - The company was informed by the stabilization agent that no stabilization actions were taken during the stabilization period [1][4]

Core Viewpoint - The stabilization period for the global offering of Huazhong Bio-B (02396) ended on January 16, 2026, with no over-allotment exercised during this period [1] Group 1 - The announcement indicates that the international offering did not involve any over-allocation of shares [1] - The over-allotment option has expired as of January 16, 2026 [1] - The company was informed by the stabilization agent that no stabilization actions were taken during the stabilization period [1]

Group 1 - The core point of the article is that Huazhong Bio-B (02396) announced the end of the stabilization period for its global offering on January 16, 2026, which is 30 days after the deadline for submitting the Hong Kong public offering application [1] - There was no over-allotment of shares under the international offering, and thus the over-allotment option was not exercised and has expired as of January 16, 2026 [1] - The company was informed by the stabilization agent that no stabilization actions were taken during the stabilization period [1]

Group 1 - The core announcement indicates that the global offering's stabilization period for Huazhang Bio-B (02396.HK) ended on January 16, 2026, which is 30 days after the deadline for submitting the Hong Kong public offering application [1] - The overallotment option was not exercised, and it has expired as of January 16, 2026 [1] - The company was informed by the stabilization agent that no stabilization actions were taken during the stabilization period [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2396） 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任 何責任。 除本公告另有界定者外，本公告所用詞彙與華芢生物科技（青島）股份有限公司（「本公司」）於 2025年12月12日刊發的招股章程（「招股章程」）所界定者具有相同涵義。 本公告乃根據香港法例第571W章《證券及期貨（穩定價格）規則》第9(2)條作出。本公告僅供參 考，並不構成任何人士收購、購買或認購本公司任何證券的要約或誘使作出要約的邀請。本 公告並非招股章程。有意投資者於決定是否投資於發售股份前，務請細閱招股章程中有關本 公司及下文所述全球發售的詳細資料。 本公告並不構成出售要約或招攬購買的要約，亦不會在有關要約、招攬或出售將屬違法的任 何司法管轄區出售任何發售股份。本公告不得直接或間接於或向美國境內（包括其領土及屬地、 美國任何州及哥倫比亞特區）或法律禁止有關發佈、刊發、分發的任何其他司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華芢生物科技（青島）股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02396 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 83,022,145 | RMB | | 1 RMB | | 83,022,145 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 ...

Key Points - A total of 113 stocks reached a 52-week high as of January 5, with notable performers including Woan Robotics (06600), China New Holdings (08125), and Dimi Life Holdings (01667) [1] - Woan Robotics achieved a high rate of 26.54%, closing at 110.000 and peaking at 118.000 [1] - China New Holdings and Dimi Life Holdings followed with high rates of 24.62% and 18.60%, respectively [1] Stock Performance Summary - **Top Performers**: - Woan Robotics (06600): Closed at 110.000, highest price 118.000, high rate 26.54% [1] - China New Holdings (08125): Closed at 0.800, highest price 0.810, high rate 24.62% [1] - Dimi Life Holdings (01667): Closed at 0.480, highest price 0.510, high rate 18.60% [1] - **Other Notable Stocks**: - XL Nanshan Samsung (07747): High rate 15.99%, closed at 44.240 [1] - XL Nanshan Samsung-U (09747): High rate 15.64%, closed at 5.625 [1] - Gaoke Bridge (09963): High rate 15.44%, closed at 1.560 [1] 52-Week Low Summary - **Top Decliners**: - Different Group (06090): Closed at 66.300, lowest price 64.750, low rate -26.50% [4] - XI Nanshan Samsung (07347): Low rate -15.96%, closed at 0.835 [4] - XI Nanshan Samsung-U (09347): Low rate -14.96%, closed at 0.108 [4] - **Other Notable Decliners**: - Huazhi Bio-B (02396): Low rate -13.80%, closed at 13.700 [4] - Easy Life Holdings (00223): Low rate -10.00%, closed at 0.124 [4] - Hongyang Real Estate (01996): Low rate -10.00%, closed at 0.028 [4]

Summary of Key Points Core Viewpoint - As of December 30, a total of 59 stocks reached their 52-week highs, with notable performers including Manman (08186), Base Champion Group (08460), and Gaoao International (08042) leading the gains in high rates of 32.63%, 23.92%, and 21.43% respectively [1]. Group 1: 52-Week Highs - Manman (08186) closed at 1.260, achieving a high rate of 32.63% [1] - Base Champion Group (08460) reached a closing price of 2.160, with a high rate of 23.92% [1] - Gaoao International (08042) closed at 0.068, marking a high rate of 21.43% [1] - Other notable stocks include Junyu Foundation (01757) with a high rate of 12.01% and TEAMWAY INTL at 11.11% [1] Group 2: 52-Week Lows - Huasheng Bio-B (02396) recorded a low rate of -15.81% with a closing price of 17.910 [3] - Ruike Bio-B (02179) reached a low rate of -14.89% with a closing price of 4.180 [3] - XI Ernan Samsung (07347) had a low rate of -12.89% with a closing price of 1.146 [3] - Other significant declines include Ziranmei (00157) at -11.36% and Yingji Tea Group (08241) at -11.11% [3] Group 3: Additional Stock Movements - Valiant International-B (09887) saw a decrease of -7.22% with a closing price of 51.000 [4] - Honglong China Real Estate (06968) dropped by -7.14% to 0.069 [4] - Other stocks with notable declines include Haowen Holdings (08019) at -6.67% and Xiaoyu Yingtong (00139) at -6.25% [4] Group 4: Minor Stock Movements - Star Health Travel (03662) decreased by -1.18% with a closing price of 0.420 [5] - Helen's (09869) saw a decline of -1.11% to 0.900 [5] - Other minor declines include Tiehuo (01029) at -1.09% and Lixin International (00191) at -1.03% [5]

Group 1 - The core viewpoint of the article highlights that Hua Yan Biotech-B (02396) has seen a significant decline in its stock price, dropping over 12% to a new low of 18.6 HKD, which is a substantial decrease from its IPO price of 38.2 HKD [1] - As of the latest report, the company's stock is trading at 18.67 HKD with a trading volume of 746.2 million HKD [1] - Hua Yan Biotech is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies [1] Group 2 - The company has a pipeline of ten candidate products scheduled for development by December 5, 2025, with seven of these being PDGF candidate drugs, including two core products, Pro-101-1 and Pro-101-2 [1] - Financially, the company has not generated any revenue from product sales, reporting net losses of 110 million, 210 million, and 130 million for the years 2023, 2024, and up to September 30, 2025, respectively [1] - The majority of the company's net losses are attributed to research and development expenses as well as administrative costs [1]

Core Viewpoint - 华芢生物-B (02396) has experienced a significant decline in stock price, dropping over 12% to a new low of 18.6 HKD, which is a 51% decrease from its IPO price of 38.2 HKD [1] Company Overview - 华芢生物 is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies [1] - As of December 5, 2025, the company has a pipeline of ten candidate products, with seven being PDGF candidate drugs, including two core products, Pro-101-1 and Pro-101-2 [1] Financial Performance - The company has not generated any revenue from product sales to date [1] - Projected net losses for the years 2023, 2024, and up to September 30, 2025, are 110 million, 210 million, and 130 million HKD respectively [1] - The majority of the net losses are attributed to research and development expenses as well as administrative costs [1]